Dasiglucagon studies show safety for children, adults experi
A next-generation glucagon analog provided rapid and effective treatment of severe hypoglycemia for children and adults with type 1 diabetes, without the need to reconstitute lyophilized powder used in traditional glucagon rescue kits.

This study aimed to evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes.

This randomized, double-blind trial included 170 adult participants with type 1 diabetes, each randomly assigned to receive a single subcutaneous dose of 0.6 mg dasiglucagon, placebo, or 1 mg reconstituted glucagon (2:1:1 randomization) during controlled insulin-induced hypoglycemia. The primary end point was time to plasma glucose recovery, defined as an increase of more than 20 mg/dL from baseline without rescue intravenous glucose. The primary comparison was dasiglucagon versus placebo; reconstituted lyophilized glucagon was included as reference.

-- Median (95% CI) time to recovery was 10 (10, 10) minutes for dasiglucagon compared with 40 (30, 40) minutes for placebo; the corresponding result for reconstituted glucagon was 12 (10, 12) minutes.

-- In the dasiglucagon group, plasma glucose recovery was achieved within 15 min in all but one participant (99%), superior to placebo and similar to glucagon (95%).

-- Similar outcomes were observed for the other investigated time points at 10, 20, and 30 min after dosing.

-- The most frequent adverse effects were nausea and vomiting, as expected with glucagon treatment.

Conclusively, Dasiglucagon provided rapid and effective reversal of hypoglycemia in adults with type 1 diabetes, with safety and tolerability similar to those reported for reconstituted glucagon injection. The ready-to-use, aqueous formulation of dasiglucagon offers the potential to provide rapid and reliable treatment of severe hypoglycemia.

Source: https://care.diabetesjournals.org/content/early/2021/04/16/DC20-2995